Enteric-coated mycophenolate sodium in pediatric lupus nephritis

a retrospective cohort study

Hsin Hsu Chou, Mei Ju Chen, Yuan-Yow Chiou

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The objective of this study was to examine the long-term efficacy and complications associated with use of enteric-coated mycophenolate sodium (EC-MPS) for treatment of pediatric lupus nephritis (LN). Methods: This was a retrospective analysis of pediatric patients treated between 1995 and 2008. Comparisons were made between patients with LN who were and were not treated with EC-MPS (MPS and non-MPS groups). The primary endpoint was survival. The secondary endpoint was time to stage 3 chronic kidney disease (CKD). Response rates, laboratory parameters, and complications were determined. Results: There were 33 patients in the MPS group and 19 patients in the non-MPS group. The MPS group had more patients with complete/partial response (72.7 vs. 31.6 %; P < 0.001) and a significantly higher survival rate (0.0 vs. 42.1 %, P < 0.001), but the groups had similar rates of stage 3 CKD. The rebound of complement 3 was more rapid in the MPS group. There were no significant between-group differences in the incidence of complications, including gastrointestinal complications. Conclusion: A limitation of this study is the heterogeneity in the timing of treatment and in the duration of follow-up. Nonetheless, our findings suggest that EC-MPS can be an effective treatment for pediatric LN.

Original languageEnglish
Pages (from-to)628-636
Number of pages9
JournalClinical and Experimental Nephrology
Volume20
Issue number4
DOIs
Publication statusPublished - 2016 Aug 1

Fingerprint

Mycophenolic Acid
Lupus Nephritis
Cohort Studies
Retrospective Studies
Pediatrics
Chronic Renal Insufficiency
Complement C3
Therapeutics
Survival Rate
Survival
Incidence

All Science Journal Classification (ASJC) codes

  • Physiology
  • Nephrology
  • Physiology (medical)

Cite this

@article{0b254aee220c41ff84d32b51cea2b446,
title = "Enteric-coated mycophenolate sodium in pediatric lupus nephritis: a retrospective cohort study",
abstract = "Background: The objective of this study was to examine the long-term efficacy and complications associated with use of enteric-coated mycophenolate sodium (EC-MPS) for treatment of pediatric lupus nephritis (LN). Methods: This was a retrospective analysis of pediatric patients treated between 1995 and 2008. Comparisons were made between patients with LN who were and were not treated with EC-MPS (MPS and non-MPS groups). The primary endpoint was survival. The secondary endpoint was time to stage 3 chronic kidney disease (CKD). Response rates, laboratory parameters, and complications were determined. Results: There were 33 patients in the MPS group and 19 patients in the non-MPS group. The MPS group had more patients with complete/partial response (72.7 vs. 31.6 {\%}; P < 0.001) and a significantly higher survival rate (0.0 vs. 42.1 {\%}, P < 0.001), but the groups had similar rates of stage 3 CKD. The rebound of complement 3 was more rapid in the MPS group. There were no significant between-group differences in the incidence of complications, including gastrointestinal complications. Conclusion: A limitation of this study is the heterogeneity in the timing of treatment and in the duration of follow-up. Nonetheless, our findings suggest that EC-MPS can be an effective treatment for pediatric LN.",
author = "Chou, {Hsin Hsu} and Chen, {Mei Ju} and Yuan-Yow Chiou",
year = "2016",
month = "8",
day = "1",
doi = "10.1007/s10157-015-1171-6",
language = "English",
volume = "20",
pages = "628--636",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",
number = "4",

}

Enteric-coated mycophenolate sodium in pediatric lupus nephritis : a retrospective cohort study. / Chou, Hsin Hsu; Chen, Mei Ju; Chiou, Yuan-Yow.

In: Clinical and Experimental Nephrology, Vol. 20, No. 4, 01.08.2016, p. 628-636.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Enteric-coated mycophenolate sodium in pediatric lupus nephritis

T2 - a retrospective cohort study

AU - Chou, Hsin Hsu

AU - Chen, Mei Ju

AU - Chiou, Yuan-Yow

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Background: The objective of this study was to examine the long-term efficacy and complications associated with use of enteric-coated mycophenolate sodium (EC-MPS) for treatment of pediatric lupus nephritis (LN). Methods: This was a retrospective analysis of pediatric patients treated between 1995 and 2008. Comparisons were made between patients with LN who were and were not treated with EC-MPS (MPS and non-MPS groups). The primary endpoint was survival. The secondary endpoint was time to stage 3 chronic kidney disease (CKD). Response rates, laboratory parameters, and complications were determined. Results: There were 33 patients in the MPS group and 19 patients in the non-MPS group. The MPS group had more patients with complete/partial response (72.7 vs. 31.6 %; P < 0.001) and a significantly higher survival rate (0.0 vs. 42.1 %, P < 0.001), but the groups had similar rates of stage 3 CKD. The rebound of complement 3 was more rapid in the MPS group. There were no significant between-group differences in the incidence of complications, including gastrointestinal complications. Conclusion: A limitation of this study is the heterogeneity in the timing of treatment and in the duration of follow-up. Nonetheless, our findings suggest that EC-MPS can be an effective treatment for pediatric LN.

AB - Background: The objective of this study was to examine the long-term efficacy and complications associated with use of enteric-coated mycophenolate sodium (EC-MPS) for treatment of pediatric lupus nephritis (LN). Methods: This was a retrospective analysis of pediatric patients treated between 1995 and 2008. Comparisons were made between patients with LN who were and were not treated with EC-MPS (MPS and non-MPS groups). The primary endpoint was survival. The secondary endpoint was time to stage 3 chronic kidney disease (CKD). Response rates, laboratory parameters, and complications were determined. Results: There were 33 patients in the MPS group and 19 patients in the non-MPS group. The MPS group had more patients with complete/partial response (72.7 vs. 31.6 %; P < 0.001) and a significantly higher survival rate (0.0 vs. 42.1 %, P < 0.001), but the groups had similar rates of stage 3 CKD. The rebound of complement 3 was more rapid in the MPS group. There were no significant between-group differences in the incidence of complications, including gastrointestinal complications. Conclusion: A limitation of this study is the heterogeneity in the timing of treatment and in the duration of follow-up. Nonetheless, our findings suggest that EC-MPS can be an effective treatment for pediatric LN.

UR - http://www.scopus.com/inward/record.url?scp=84944908965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944908965&partnerID=8YFLogxK

U2 - 10.1007/s10157-015-1171-6

DO - 10.1007/s10157-015-1171-6

M3 - Article

VL - 20

SP - 628

EP - 636

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

IS - 4

ER -